Business
Globus Medical Reports First Quarter 2026 Results
AUDUBON, Pa., May 07, 2026 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology company, today announced its financial results for the first quarter ended March 31, 2026. First Quarter 2026: Worldwide net sales were $759.9 million, an increase of 27.0%, or an increase of 25.5% on a constant currency basis.Base business, excluding Nevro, net sales were $677.2 million, an increase of 13.2%, or an increase of 11.2% on a constant currency basis.GAAP net income
About this update from Globus Medical, Inc.
[{"type":"image","alt":"Globus Medical","displaySize":"","headline":null,"caption":"Globus Medical","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":236,"url":"https://media.zenfs.com/en/globenewswire.com/00da90d72bee150b4be4104613ae2ce4"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/10w_k4YiJAOEMsQVQ2e.Rw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTMzMA--/https://media.zenfs.com/en/globenewswire.com/00da90d72bee150b4be4104613ae2ce4","width":300,"height":236}},"lazy":false},{"type":"text","content":"AUDUBON, Pa., May 07, 2026 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology company, today announced its financial results for the first quarter ended March 31, 2026.","length":209,"tagName":"p"},{"type":"text","content":"First Quarter 2026:","length":19,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Worldwide net sales were $759.9 million, an increase of 27.0%, or an increase of 25.5% on a constant currency basis.","length":116,"tagName":"p"}]},{"val":[{"type":"text","content":"Base business, excluding Nevro, net sales were $677.2 million, an increase of 13.2%, or an increase of 11.2% on a constant currency basis.","length":138,"tagName":"p"}]},{"val":[{"type":"text","content":"GAAP net income for the quarter was $124.3 million.","length":51,"tagName":"p"}]},{"val":[{"type":"text","content":"GAAP diluted earnings per share (“EPS”) was $0.90, an increase of 66.6%. Non-GAAP diluted EPS was $1.12, an increase of 64.7%.","length":126,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":431,"olType":false},{"type":"text","content":"“We’re off to a strong start in 2026 with 27% overall revenue growth and record first quarter earnings. Organic revenue grew over 13%, driven by share gains and procedural volume strength in core spine, while Enabling Technologies delivered against its pipeline and continued to expand its customer base,” commented Keith Pfeil, President and Chief Executive Officer. “Disciplined execution on manufacturing and supply chain initiatives, as well as structural cost actions, coupled with operating leverage on higher volumes, drove margin expansion in excess of sales growth, which we expect to favorably impact full-year results. Our strategic priority remains centered on achieving improved surgical outcomes through the Globus ecosyst...